Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Zanzalintinib in Moderate Hepatic Impairment
NCT06962332Phase 1Recruiting
- Sponsor
- Exelixis, Inc.
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanzalintinib in solid tumor (2 arms), sponsored by Exelixis, Inc. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time 0 to Time t Corresponding to the Last Quantifiable Concentration, Maximum Observed Plasma Drug Concentration and 1 more. Started May 2025; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06962332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06962332.